Efruxifermin safe, well-tolerated in patients with NASH with advanced fibrosis

Efruxifermin safe, well-tolerated in patients with NASH with advanced fibrosis

Among patients with FIB-4 nonalcoholic steatohepatitis at greater risk for progression to end stage liver disease, researchers at the International Liver Congress found efruxifermin 50 mg was safe and well-tolerated.“Consistent with the Balanced Main study, [efruxifermin (EFX)] treatment appeared to improve liver histology,” Stephen Harrison, MD, medical director, Pinnacle Clinical Research, The University of Texas, visiting professor of hepatology at the University of Oxford, said during his presentation.“The observed reductions in noninvasive markers of liver injury andRead More

Share on facebook
Share on twitter
Share on linkedin